David Shook - 15 Jul 2024 Form 4 Insider Report for Nkarta, Inc. (NKTX)

Role
Chief Medical Officer, Head of Research & Development
Signature
/s/ Alicia Hager, as Attorney-in-Fact
Issuer symbol
NKTX
Transactions as of
15 Jul 2024
Net transactions value
$0
Form type
4
Filing time
31 Jul 2024, 16:45:43 UTC
Previous filing
20 Jun 2024
Next filing
23 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTX Common Stock Award $0 +23,421 +20% $0.000000 139,945 15 Jul 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTX Stock Option (right to buy) Award $0 +30,000 $0.000000 30,000 15 Jul 2024 Common Stock 30,000 $7.02 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction is inadvertently filed late due to an administrative error.
F2 Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on August 20, 2025. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
F3 This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following July 15, 2024.

Remarks:

Chief Medical Officer, Head of Research & Development